Talquetamab Continues To Demonstrate High Overall Response Rates in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - April 1, 2025 834 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MonumenTAL-1 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR How Does Smoking Increase Your Cancer Risk? An Expert Q&A July 27, 2021 Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or... February 19, 2026 Patient Guide on Bone Health in Cancer Now Available Also in French January 19, 2026 Colon capsule endoscopy – reshaping bowel cancer diagnosis April 14, 2021 Load more HOT NEWS Machine Learning-Based Model Shows Promise for Indicating Response to Immune Checkpoint... What Are Social Determinants of Health and How Do They Affect... Revumenib Shows Promise in Treating Advanced Acute Myeloid Leukemia High Sensitivity of Mismatch Repair–Deficient Locally Advanced Rectal Cancer to Single-Agent...
